[{"orgOrder":0,"company":"Versameb","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$6.3 million","upfrontCash":"Undisclosed","newsHeadline":"Versameb Raises CHF 6 Million and Strengthens Team to Advance its VERSagile Technology Platform Towards Clinical Trials","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"July 2020","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical"},{"orgOrder":0,"company":"Versameb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Versameb to Present Novel Data on Its Lead Asset, VMB-100 at 9th International mRNA Health Conference","therapeuticArea":"Urology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Urology","graph2":"Preclinical"},{"orgOrder":0,"company":"Versameb","sponsor":"Touchlight","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Touchlight and Versameb Announce GMP Manufacturing Supply Agreement","therapeuticArea":"Urology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Urology","graph2":"Preclinical"},{"orgOrder":0,"company":"Versameb","sponsor":"Touchlight","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Touchlight\u2019s Enzymatic Doggybone DNA used in the Manufacture of Versameb\u2019s VMB-100 for First-in-human Clinical Study","therapeuticArea":"Urology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Urology","graph2":"Preclinical"}]
Find Clinical Drug Pipeline Developments & Deals by Versameb
VMB-100, a potency enhanced messenger ribonucleic acid (mRNA) encoding human insulin-like growth factor-1 (IGF-1), is being developed to treat chronic stress urinary incontinence (SUI).
The agreement enables Versameb to use Touchlight’s proprietary doggybone DNA (dbDNA™) vector technology to support the development of novel mRNA-based therapeutics, including VMB-100, addressing unmet needs in urology and oncology.
VMB-100 has demonstrated first-in-class potential for treatment for Stress Urinary Incontinence (SUI) in a pre-clinical animal model showing regeneration and functional restoration of the urinary sphincter. VMB-100 shows therapeutic potential in Stress Urinary Incontinence.
Molecular engineering mRNA sequences with the VERSagile technology platform generates molecules optimized for improved protein secretion and allows for modulation of different therapeutic targets.